Summary:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of PRX012 in Alzheimer's Disease.
Qualified Participants Must:
• Be 60-85
•
Have BMI between 18-32
•
Be experiencing memory loss
Qualified Participants May Receive:
- Compensation for time and travel
- No insurance necessary and travel included